Is there evidence supporting evening‑prime‑rose oil as a first‑line treatment for mild‑to‑moderate cyclic mastalgia in otherwise healthy women of reproductive age, and what dosage is recommended?

Evening Primrose Oil for Mastalgia: Evidence Summary

Evening primrose oil (EPO) should NOT be recommended as first-line treatment for cyclic mastalgia, as the highest quality evidence demonstrates it is no more effective than placebo for pain relief.

Key Evidence Analysis

The most recent and rigorous systematic review and meta-analysis 1 (2021,13 trials, 1,752 patients) definitively shows that EPO provides no significant difference in pain reduction compared to placebo. This directly contradicts the question's premise about EPO as first-line therapy.

What the Evidence Actually Shows

Against EPO Efficacy:

• The 2021 meta-analysis found EPO showed no difference versus placebo, topical NSAIDs, danazol, or vitamin E for achieving pain relief 1
• Number of patients achieving pain relief was statistically equivalent across all groups 1
• This is the highest quality, most recent evidence and should guide practice

Supporting EPO (Lower Quality Evidence):

• Older studies from 1999 2 and 1991 3 reported 97% and 77% response rates respectively, but these lack the rigor of modern meta-analyses
• A 2020 observational study 4 (1,015 patients) found EPO superior to paracetamol, but this was not placebo-controlled
• A 2024 study 5 showed combination EPO + vitamin E reduced pain by 4.5 points versus 2.0 for placebo, but this single study contradicts the larger meta-analysis

Critical Interpretation

The 2021 meta-analysis 1 must take precedence as it:

• Synthesizes 13 trials versus individual studies
• Uses rigorous methodology with random-effects modeling
• Represents the most comprehensive and recent evidence
• Directly addresses efficacy versus placebo

Clinical Recommendations

For Mild-to-Moderate Cyclic Mastalgia:

1. First-line approach: Reassurance and observation

   • 14-20% spontaneous resolution within 3 months 6
   • Most patients experience decreasing severity over time 6

2. If treatment required: Consider alternatives to EPO

   • Topical NSAIDs (equivalent efficacy to EPO per meta-analysis) 1
   • Well-fitted supportive bra
   • Avoid hormonal triggers if identified

3. EPO considerations:

   • May be offered as trial therapy given excellent safety profile (no increased adverse events versus placebo) 1
   • If used: 1,000-1,300 mg twice daily 5, 4
   • Duration: 6 months minimum for assessment 5, 7
   • Set realistic expectations: likely no better than placebo

Factors Affecting Treatment Response

If EPO is attempted, screen for conditions that impair efficacy 4:

• Iron deficiency (check ferritin)
• Overt hypothyroidism or Hashimoto thyroiditis (check TSH)
• Hormone replacement therapy use
• Levonorgestrel IUD

Correcting these underlying conditions may resolve mastalgia without EPO 4.

Important Caveats

• The ACR Appropriateness Criteria [6-8] do not specifically endorse EPO as first-line therapy
• Cyclical mastalgia has extremely low cancer risk (0-3%) when isolated symptom 8
• Imaging beyond routine screening is not indicated for non-focal cyclical pain 8
• 60% recurrence rate within 2 years regardless of treatment 6

Bottom line: The evidence does not support EPO as first-line treatment. Reassurance, observation, and addressing underlying medical conditions should precede any pharmacologic intervention. If medication is necessary, EPO's safety profile makes it reasonable to try, but patients must understand it likely works no better than placebo.